USP7 Inhibitor Compounds for Selective Antineoplastic Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for cancer, particularly those targeting deubiquitylating enzymes like USP7, face challenges such as toxicity and drug resistance, and there is a lack of reliable high-throughput assays for screening DUB inhibitors or activators, hindering the development of clinically effective compounds.
Innovation Solution
Development of novel compounds with the structure of Formula (I), which are used to inhibit cysteine protease activity of deubiquitylating enzymes, particularly USP7, for therapeutic applications in antineoplastic treatments, including combination therapies with genotoxic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bortezomib is used for extended treatment, then cancer therapy effectiveness is improved, but toxicity and drug resistance increase
Solution Approach 1:
The patent extracts and targets a specific component (USP7 deubiquitylating enzyme) within the broader ubiquitin-proteasome pathway, rather than inhibiting the entire pathway as bortezomib does. This selective inhibition of USP7 aims to achieve cancer therapeutic effects while avoiding the systemic toxicity and resistance issues associated with broad proteasome inhibition.
Solution Approach 2:
The invention applies local quality by designing compounds that specifically target USP7 enzyme activity at particular molecular sites, allowing differentiated inhibition of cancer cell survival mechanisms while sparing normal cells. The compounds are engineered to interact with specific residues in the USP7 active site, creating localized therapeutic action with reduced off-target effects.
2Reliability
If DUB inhibitors are developed for cancer treatment, then therapeutic effectiveness is improved, but lack of reliable high-throughput assays hinders compound development
Solution Approach 1:
The patent establishes preliminary action by creating and validating high-throughput screening assays for DUB inhibition before large-scale compound development. These assays enable rapid evaluation of potential DUB inhibitors, allowing the field to progress from theoretical targeting to practical drug discovery by providing reliable screening capabilities upfront.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively inhibit USP7, potentially leading to synergistic tumor cell death and providing a therapeutic option for various cancers with reduced toxicity and improved treatment efficacy.
Implementation Method 1
inhibit cysteine protease activity of deubiquitylating enzymes, particularly USP7
Data Source
AI summary
Disclosed are novel compounds which are useful as therapeutics, especially in anti-neoplastic therapy and in other therapeutic regimes where cysteine protease inhibition is implicated.